Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 7, 2014; 20(21): 6691-6697
Published online Jun 7, 2014. doi: 10.3748/wjg.v20.i21.6691
Published online Jun 7, 2014. doi: 10.3748/wjg.v20.i21.6691
Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer
Wei Wang, Li-Rong Zhao, Xiu-Qiang Lin, Fen Feng, Department of Gastroenterology, Foshan First People’s Hospital, Foshan 520800, Guangdong Province, China
Author contributions: Wang W and Feng F wrote the manuscript; Zhao LR and Lin XQ were attending doctors and performed clinical treatment; Feng F reviewed the manuscript; all authors have read and approved the final manuscript.
Correspondence to: Fen Feng, MD, Department of Gastroenterology, Foshan First People’s Hospital, No. 81 Lingnan Dadaobei, Chancheng District, Foshan 520800, Guangdong Province, China. ffen@fsyyy.com
Telephone: +86-757-83161035 Fax: +86-757-83812566
Received: October 13, 2013
Revised: February 20, 2014
Accepted: March 19, 2014
Published online: June 7, 2014
Processing time: 235 Days and 20.1 Hours
Revised: February 20, 2014
Accepted: March 19, 2014
Published online: June 7, 2014
Processing time: 235 Days and 20.1 Hours
Core Tip
Core tip: This is the first report of reversible posterior leukoencephalopathy syndrome (RPLS) induced by bevacizumab in China. RPLS is a rare complication of bevacizumab, but may present with life-threatening symptoms such as coma. Sudden blood pressure increase is the most common risk factor, and early recognition and prompt control of blood pressure may make this complication reversible.